TITLE

INDEPENDENT CLINICAL TRIALS TO TEST DRUGS: THE NEGLECTED REFORM

AUTHOR(S)
RODWIN, MARC A.
PUB. DATE
December 2012
SOURCE
Journal of Health Law & Policy;2012, Vol. 6 Issue 1, p113
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the reform proposals precluding the bias in the clinical trials used in drug testing in the U.S. It mentions that the federal government has pursued alternative strategies to counter bias when the reform proposal was neglected for over half a century due to the opposition of the pharmaceutical industry. It says that the creation of a governmental center to assess drug effectiveness and compare the costs and benefits of alterative drug therapies is proposed by doctors Wayne Ray, Marie Griffin, and Jerry Avorn. Moreover, the regulations of the U.S. Food and Drug Administration (FDA) regarding clinical investigations had not been finalized by October 1979.
ACCESSION #
85212481

 

Related Articles

  • Pitch Perfect. Johnston, Josephine // Scientist;Jan2012, Vol. 26 Issue 1, p24 

    The article focuses on the issue of academic detailing related to the pharmaceutical industry in the U.S. It highlights the American Recovery and Reinvestment Act, which directed funds amounting 150 billion dollars to health care. It states that comparative effectiveness research is different...

  • The Battle Over Biosimilars. Agres, Ted // Drug Discovery & Development;Apr2011, Vol. 14 Issue 4, p10 

    The article focuses on the attempts to defund the Affordable Care Act in the U.S. Congress in 2011 which could have a huge impact on the exclusivity for biological drugs as well as the branded biotechnology and pharmaceutical industries. It is believed that the success of the attempts will...

  • Executive Summary.  // United States Pharmaceuticals & Healthcare Report;Q2 2010, p5 

    The article presents an overview of the U.S. pharmaceutical market as of 2010. There has been a 4.4% increase in total pharmaceutical sales in 2009, including prescription and over-the-counter (OTC) drugs. It expects a compound annual growth rate of 2.17 for the market over the next five years....

  • Comparative Effectiveness Research in the Regulatory Setting. Siegel, Jay P.; Rosenthal, Norman; Buto, Kathleen; Lilienfeld, Sean; Thomas, Adrian; Odenthal, Susan // Pharmaceutical Medicine - New Zealand;2012, Vol. 26 Issue 1, p5 

    Consumers today have access to more information regarding everyday decisions than ever before. Healthcare is no exception. The US health reform laws signed in March 2010, provided a vehicle for systematically facilitating the application of this trend to the US healthcare system through the...

  • Tackling Transparency. Wechsler, Jill // Pharmaceutical Executive;Jul2010, Vol. 30 Issue 7, p22 

    The article focuses on the mandates in the healthcare reform legislation in the U.S. concerning the transparency in providing drug information, including formulary listings, out-of-pocket costs and comparative assessments. It notes that a Transparency Initiative is launched by the Food & Drug...

  • FDA and Pharma Seek Better Ways to Assess Drug Safety, Efficacy in Clinical Trials. Mitka, Mike // JAMA: Journal of the American Medical Association;6/27/2012, Vol. 307 Issue 24, p2576 

    The article presents information on the need of improvement in drug testing procedures as suggested by the Food and Drug Administration (FDA) of the U.S. and the pharmaceutical manufacturers. The changes in the assessment of the trial data will be helpful in streamlining the improvement...

  • From the Creators of the Great Society. SCHWARZ, FRED // National Review;9/21/2009, Vol. 61 Issue 17, p26 

    The article urges that the health care reform measures proposed by President Barack Obama are politically unsound due to the poor historical record of progress among programs that bolster the power of the federal government. Programs such as the U.S. Food and Drug Administration and the Fair...

  • Correction: Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation.  // PLoS Clinical Trials;Jan2009, Vol. 6 Issue 1, p0117 

    Several corrections to the article "Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation," by K. Rising et al are presented.

  • Electronic Data in Clinical Investigations. Heisey, Colleen // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p18 

    The article reports on the revision of the U.S. Food and Drug Administration's (FDA) draft guidance document addressing comments associated to the pharmaceutical industry. FDA revises the source data from clinical investigations incorporated with an electronic case report form's (eCRF)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics